Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01048281 |
Recruitment Status
:
Recruiting
First Posted
: January 13, 2010
Last Update Posted
: July 14, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Stomach Cancer Gastro-Esophageal(GE) Junction Cancer Gastric (Stomach) Cancer Esophageal Cancer Gastrointestinal Stromal Tumor (GIST) | Procedure: Blood draw Procedure: Tissue tumor biopsy |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma |
Study Start Date : | August 2002 |
Estimated Primary Completion Date : | January 2099 |
Estimated Study Completion Date : | January 2099 |

- p53 activity by routine pathologic analysis [ Time Frame: time of collection ]
- NER activity by routine pathologic analysis [ Time Frame: time of collection ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:1. Over 18 2. Diagnosed with gastric or esophageal cancer OR at an increased hereditary risk for upper GI cancer
Exclusion Criteria:1. Under 18 2. No family or personal history of gastric or esophageal cancer

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01048281
Contact: Meredith Mills | (650) 724-5223 | bluett@stanford.edu |
United States, California | |
Stanford University School of Medicine | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Meredith Mills 650-724-5223 bluett@stanford.edu | |
Principal Investigator: James M Ford | |
Sub-Investigator: Hanlee P. Ji | |
Sub-Investigator: Vandana Bhardwaj Sharma |
Principal Investigator: | James M Ford | Stanford University |
Responsible Party: | Stanford University |
ClinicalTrials.gov Identifier: | NCT01048281 History of Changes |
Other Study ID Numbers: |
GIUPR0001 76274 ( Other Identifier: Stanford University Alternate IRB Approval Number ) CA109190 ( Other Identifier: NIH ) SU-11022007-787 ( Other Identifier: Stanford University ) |
First Posted: | January 13, 2010 Key Record Dates |
Last Update Posted: | July 14, 2016 |
Last Verified: | July 2016 |
Additional relevant MeSH terms:
Esophageal Neoplasms Gastrointestinal Stromal Tumors Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms |
Digestive System Diseases Esophageal Diseases Gastrointestinal Diseases Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Stomach Diseases |